Teva Pharmaceuticals and Medincell announced that the FDA accepted their supplemental New Drug Application for UZEDY, a long-acting injectable risperidone formulation, for the maintenance treatment of bipolar I disorder in adults. UZEDY is already approved in the US for schizophrenia treatment and is administered subcutaneously every one or two months. This application leverages existing UZEDY clinical data combined with prior FDA findings on the safety and efficacy of other risperidone formulations for bipolar I disorder.
This FDA acceptance signifies a potential advancement in bipolar I disorder treatment. Long-acting injectables offer a critical advantage for managing this chronic condition, where adherence to daily oral medication regimens is often a significant challenge impacting treatment success. This new potential indication for UZEDY could offer patients a more convenient and reliable way to receive medication, potentially leading to better symptom control and improved long-term outcomes. This is crucial given the severe impact of bipolar I disorder, characterized by debilitating manic and depressive episodes that significantly affect a person’s mood, behavior, and daily functioning.
UZEDY utilizes Medincell’s BEPO technology, enabling sustained release of risperidone following subcutaneous injection. The sNDA submission relies on existing data from UZEDY’s schizophrenia trials (RISE and SHINE) along with established knowledge of risperidone’s effectiveness in bipolar I disorder. Teva will lead the regulatory process and commercialization efforts, while Medincell is eligible for royalties on net sales if approved.
This sNDA acceptance positions UZEDY as a potential first-in-class long-acting injectable treatment for bipolar I disorder. A positive FDA decision would not only expand Teva’s market reach but also significantly improve treatment options for patients struggling with adherence to current therapies. This development underscores the potential of long-acting injectables to address persistent challenges in managing chronic mental health conditions.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
